Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPN

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial compared parenchyma-sparing surgery versus more extensive resection for solid pseudopapillary tumors — based on my specific tumor location and size, which surgical approach does my care team think is most appropriate for me, and why?
2. 2The trial tracked R0 resection rates, meaning whether the tumor is removed with clear margins — how confident is my surgeon that a margin-negative resection can be achieved with a less extensive operation in my case?
3. 3Two of the key safety outcomes this study measured were new-onset diabetes and pancreatic enzyme-dependent malabsorption after surgery — given my overall health, how much of a risk are these long-term complications for me personally?
4. 4Since this trial has already completed and collected data on recurrence-free survival, has my doctor seen or reviewed any published findings from it, and do those results influence the surgical approach they're recommending for me?
5. 5Solid pseudopapillary tumors are generally considered low-grade malignancies — given that, should I be thinking about the tradeoff between preserving more pancreatic tissue versus ensuring the most thorough possible cancer clearance, and how does my doctor weigh those two goals?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.